Companies House · 02354269

AMGEN LIMITED

UK registered company, private limited company, incorporated 1 Mar 1989.

Active
50
Public contracts
0
Spend payments
Total spend

AMGEN LIMITED is a UK company registered at Companies House under number 02354269. This page links its registry record to its activity in UK public procurement — the contracts it has been awarded and the transparency-spend payments recorded against it.

Companies House record

Company number
02354269
Status
Active
Company type
Private Limited Company
Incorporated
1 Mar 1989
Country of origin
United Kingdom
Registered office
216 CAMBRIDGE SCIENCE PARK, CAMBRIDGE, CAMBRIDGESHIRE, CB4 0WA, ENGLAND
Nature of business (SIC)
72110 - Research and experimental development on biotechnology
Accounts category
FULL
View source on data.gov.uk

Public sector contracts

Contract awards linked to AMGEN LIMITED.

ProcurementBuyerAwardedValue
NHS National Framework for the supply of Ustekinumab - 1 September 2024NHS England
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025NHS England
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025NHS England
NP49425 Generic and Biosimilar Transition MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
NP49425 Generic and Biosimilar Transition MedicinesThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Medicinal Products and Pharma Funded Homecare ServicesProcurement and Logistics Service
Medicinal Products and Pharma Funded Homecare ServicesProcurement and Logistics Service
Medicinal Products and Pharma Funded Homecare ServicesProcurement and Logistics Service
Medicinal Products and Pharma Funded Homecare Services (5315742) - Pre - Market EngagementRegional Business Services Organisation Procurement and Logistics Service
Medicinal Products and Pharma Funded Homecare Services (5315742) - Pre - Market EngagementRegional Business Services Organisation Procurement and Logistics Service
Biosimilars and Biologics with Associated Medicines Homecare ServicesVelindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales UHBs & Trusts
NHS Framework Agreement, Branded Medicines for London and South of England and Bevacizumab for North of England and Midlands and EastNHS England
NHS Framework Agreement, Branded Medicines for London and South of England and Bevacizumab for North of England and Midlands and EastNHS England
NHS Framework Agreement, Branded Medicines for London and South of England and Bevacizumab for North of England and Midlands and EastNHS England
NHS Framework for the Midlands and East, Branded Medicines – Tranche A and Annual TrancheThe NHS Commissioning Board (operating under the name of NHS England)
NHS Framework for the Midlands and East, Branded Medicines – Tranche A and Annual TrancheThe NHS Commissioning Board (operating under the name of NHS England)
Invitation to offer for NHS Framework for the North of England, Branded Medicines – Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi®)The NHS Commissioning Board (operating under the name of NHS England)
NHS National Proprietary Category Tender - 1 May 2024NHS England
UstekinumabVelindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales UHBs & Trusts
Transitional Drugs 3Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales UHBs & Trusts
Biologic and Biosimilar MedicineseTenderwales
NHS Framework Agreement for Branded Medicines – Tranche A London and South of England and Adult Influenza (National) - 01 September 2025NHS England
Romiplostim (NPlate®)The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Romiplostim (NPlate®)The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Cytokine ModulatorsThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Erythropoietin Stimulating Agents & Intravenous IronThe Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Proprietary DrugsVelindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales LHB's and Trusts)
Invitation to offer for NHS London Branded Medicines - Tranche A and AnnualNHS England
NHS Framework for the Midlands and East, Branded Medicines – Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.The NHS Commissioning Board (operating under the name of NHS England)
NHS Framework, North of England, Branded Medicines - Tranche A and Annual TrancheThe NHS Commissioning Board (operating under the name of NHS England)
NHS Framework, North of England, Branded Medicines - Tranche A and Annual TrancheThe NHS Commissioning Board (operating under the name of NHS England)
NHS Framework for North of England Branded Medicines - Tranche A and Annual TrancheNHS England
NHS Framework for North of England Branded Medicines - Tranche A and Annual TrancheNHS England
NHS Framework for Midlands and East Branded Medicines - Tranche B and Annual TrancheNHS England
National Framework Agreement for Adalimumab Injection 1 April 2023NHS England
NHS National Framework Agreement for the supply of Eculizumab - 1 Feb 2024NHS England
NHS National Framework for the supply of Ustekinumab - 1 September 2024NHS England
NP47923a Adalimumab, NP47923b Tocilizumab and NP47923c EculizumabThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
NP47923a Adalimumab, NP47923b Tocilizumab and NP47923c EculizumabThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Ustekinumab and OmalizumabThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Romiplostim (Nplate®)The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Romiplostim (Nplate®)The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
NP40725 Erythropoietin Stimulating AgentsThe Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
NHS Branded Medicines Framework for North of England and Midlands and East of England - 1 March 2024NHS England
NHS National Framework for Denosumab Injection commencing 1st January 2026NHS England North East & Yorkshire29 Sept 2025£15.1m
NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025NHS England30 Jun 2025£986.3m
NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza NationalNHS England24 Jun 2025£261.9m
CM/TNS/24/5711 -NHS Framework for the supply of UstekinumabNHS England12 Aug 2024£230m
NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024NHS England4 Apr 2024£1bn
NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024NHS England26 Jan 2024£688m

Supplier identities

How this company appears as a supplier across the data.

FAQs about AMGEN LIMITED

Is AMGEN LIMITED an active company?

AMGEN LIMITED (company number 02354269) is recorded as "Active", incorporated on 1 Mar 1989.

What does AMGEN LIMITED do?

Its Companies House nature-of-business (SIC) is: 72110 - Research and experimental development on biotechnology.

Has AMGEN LIMITED won UK public-sector contracts?

Yes — 50 public-sector contract awards are linked to this company in our data.

Where is AMGEN LIMITED based?

Its registered office is 216 CAMBRIDGE SCIENCE PARK, CAMBRIDGE, CAMBRIDGESHIRE, CB4 0WA, ENGLAND.

Understand any company's public-sector footprint

Enable links Companies House to live procurement and spend data — see contracts, buyers and payments for any UK supplier.

Get in touch with Enable